SCHEMBL7188423

SCHEMBL7188423

CCCCCCCCCCCCCCCCCCCCOP(=O)(O)OCC[N+](C)(C)C

nearest known ligand 0.70

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 2/20 0.70
AKT1 P31749 2/20 0.70
ESR1 P03372 1/20 0.70
ADORA3 P0DMS8 1/20 0.70
CDC25A P30304 1/20 0.70
AGTR1 P30556 1/20 0.70
ADRA1A P35348 1/20 0.70
KCNH2 Q12809 1/20 0.70
LPAR3 Q9UBY5 6/20 0.58
LPAR2 Q9HBW0 5/20 0.58
LPAR1 Q92633 2/20 0.58
FABP3 P05413 1/20 0.56
PRKD3 O94806 2/20 0.50
PRKCG P05129 2/20 0.50
PRKCB P05771 2/20 0.50
PRKCA P17252 2/20 0.50
PRKCH P24723 2/20 0.50
PRKCI P41743 2/20 0.50
PRKCE Q02156 2/20 0.50
PRKCQ Q04759 2/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL905581 1.00 LMNA (0.70) LMNAAKT1ESR1ADORA3CDC25A
SCHEMBL2693659 1.00 LMNA (0.70) LMNAAKT1ESR1ADORA3CDC25A
SCHEMBL14447829 1.00 LMNA (0.70) LMNAAKT1ESR1ADORA3CDC25A
SCHEMBL14447816 1.00 LMNA (0.70) LMNAAKT1ESR1ADORA3CDC25A
SCHEMBL62054 1.00 LMNA (0.70) LMNAAKT1ESR1ADORA3CDC25A
SCHEMBL14447974 1.00 LMNA (0.70) LMNAAKT1ESR1ADORA3CDC25A
SCHEMBL2695075 1.00 LMNA (0.70) LMNAAKT1ESR1ADORA3CDC25A
SCHEMBL60426 1.00 LMNA (0.70) LMNAAKT1ESR1ADORA3CDC25A
Tetradecylphosphocholine SCHEMBL1152910 1.00 LMNA (0.70) LMNAAKT1ESR1ADORA3CDC25A
SCHEMBL5707895 1.00 LMNA (0.70) LMNAAKT1ESR1ADORA3CDC25A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070167408-A1 NOVEL ALKYL PHOSPHOLIPID DERIVATIVES WITH REDUCED CYTOTOXICITY AND USES THEREOF ZENTARIS GMBH (DE) 2007-07-19 US disclosed
WO-2007071658-A2 ALKYL PHOSPHOLIPID DERIVATIVES WITH REDUCED CYTOTOXICITY AND USES THEREOF ÆTERNA ZENTARIS GMBH (DE) 2007-06-28 WO disclosed
EP-1800684-A1 Novel alkyl phospholipid derivatives and uses thereof Zentaris GmbH (DE) 2007-06-27 EP disclosed
US-6506393-B2 Administering phosphocholine compound; leishmaniasis treatment ZENTARIS AG (DE) 2003-01-14 US disclosed
US-20010008885-A1 Methods of treating protozoal diseases MAX-PLANCK-GESSELLSCHAFT ZUR FORDERUNG DER WISSENSCHAFTEN E. V. 2001-07-19 US disclosed
US-6254879-B1 QUATERNARIUMAMINOETHYLPHOSPHATES Max-Planck-Gessellschaft zun Förderung der Wissenschaften e.V. (DE) 2001-07-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20010008885-A1 Methods of treating protozoal diseases HRH2, HRH1, HRH4 LMNA 1525/4885AKT1 2973/4885ESR1 4651/4885
US-20070167408-A1 NOVEL ALKYL PHOSPHOLIPID DERIVATIVES WITH REDUCED CYTOTOXICITY AND USES THEREOF PHOSPHO1, PTDSS1, PTDSS2 LMNA 2308/4885AKT1 1230/4885ESR1 4671/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.